EUCTR2013-000652-18-BE进行中（未招募）不适用
Pharmacokinetics study of piperacillin-tazobactam and meropenem in obese patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients >= 18 years
- •-All hospitalized obese patient (BMI >= 30 kg/m²) treated by intraveinous piperacillin-tazobactam or meropenem for an infection (proven or suspected)
- •-All hospitalized non-obese patient (BMI <= 30 kg/m²) treated by intraveinous piperacillin-tazobactam or meropenem for an infection (proven or suspected)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •-Pregnant woman
- •-Severe sepsis or septic shock
研究者
相似试验
招募中
4 期
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.cystic fibrosis2024-518337-29-00Medical University Of Vienna18
招募中
不适用
PK of Piperacillin/Tazobactam in Adults Undergoing ECMOAcute Respiratory Failure With HypoxiaNCT03467854Columbia University10
进行中（未招募）
1 期
Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMAsepsis or septic shockMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-003496-36-FRHospices Civils de Lyon60
招募中
不适用
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal PopulationsEarly-Onset Neonatal SepsisNCT06076200Shandong University50
已完成
4 期
The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapyThe patients who have blood purification therapy in the intensive care unit and who need to take Tazobactam / Piperacillin [2.25g*2times/day]JPRN-UMIN000019162Hyogo college of medicine10